CLASS II Drug recall · Reported 12 Feb 2014 · FDA Enforcement Report

Hydralazine HCL Tablets, USP, 50 mg in a single blister package recalled

Teva Pharmaceuticals USA is recalling Hydralazine HCL Tablets, USP, 50 mg in a single blister package, distributed nationwide in the US. The recall was initiated on 18 Dec 2013 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot # 6A201018VA; Exp. 01/14.
Quantity recalled112,800 tablets

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-1075-2014
FDA event ID
67141
Recalling firm
Teva Pharmaceuticals USA, Horsham, PA
Classification
Class II
Status
Terminated
Recall initiated
18 Dec 2013
FDA classified
4 Feb 2014
Reported
12 Feb 2014
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

18 Dec 2013Recall initiated by company
4 Feb 2014Classified by FDA+48 days
12 Feb 2014Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Hydralazine HCL Tablets, USP, 50 mg in a single blister package, Rx only, Manufactured in Czech Republic by: Teva Czech Industries s.r.o. Opava-Komarov, Czech Republic, Distributed by Goldline Laboratories, Sellersville, PA, NDC 00182-0555-89 (carton) and 00182-0555-00 (single blister).

Where it was distributed

Nationwide

Nationwide

Questions about this recall

Why was it recalled?

Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.

Which lots are affected?

Lot # 6A201018VA; Exp. 01/14.

Where was it sold?

Nationwide

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

1 other product · FDA event 67141

This product is part of a recall event; the main page for the event is Hydralazine HCL Tablets, USP, 25 mg in a single blister package recalled.

More recalls from Teva Pharmaceuticals USA

All 280

Other Hydralazine recalls

All 17